SAN FRANCISCO, Aug. 30, 2016 /PRNewswire/ -- goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, announced today that CMIC HOLDINGS has chosen goBalto to further bolster CMIC HOLDINGS' clinical study startup process throughout Asia.
CMIC HOLDINGS is using goBalto's flagship product, Activate, for multi-country studies being conducted in Malaysia, Singapore, Taiwan, Philippines, Thailand, Japan, and South Korea. CMIC HOLDINGS is benefiting from Activate's robust library of country-specific workflows and management-based approach to site activation.
Activate allows CMIC HOLDINGS to track country and site milestones, streamlining the study startup process by ensuring clinical operations has real-time status updates, and ensuring efficiency gains by eliminating "hidden" communications created by relying on email and manual spreadsheets. CMIC HOLDINGS engages collaboratively with investigator sites using Activate to improve the communication process and to ultimately minimize the time to obtain critical documents.
Kazuo Nakamura, Chairman & CEO, at CMIC HOLDINGS stated, "Activate allows us to minimize risk in starting clinical trials and ensure compliance. Activate's workflows standardize processes and guide our clinical operations teams to complete and track specific documents and tasks for any site, country, or study based on regulatory requirements and our company's standard operating procedures (SOPs)."
"Activate allows the project management team at CMIC HOLDINGS to drive discussions and decision-making on bottlenecks impacting site activation. Significantly, time is not wasted charting data and compiling status updates, a practice that is typical with older methods, such as Excel," said Jae Chung, goBalto's founder and president. "The adoption of Activate at CMIC HOLDINGS further bolsters our international expansion and growth in the number of global clinical trials utilizing our industry first end-to-end study startup platform to accelerate clinical trials and speed therapies to patients in need."
About CMIC HOLDINGS Co., Ltd.
CMIC Group started business in 1992 as the first CRO in Japan, and the company today provides comprehensive support services for development, manufacturing, sales, and marketing of pharmaceutical industry. Also, the company operates to respond to diversifying needs by managing the Healthcare Business sector and developing and selling diagnostic pharmaceuticals and orphan drugs. CMIC Group has developed a unique business model that we call "Pharmaceutical Value Creator (PVC)" based on our abundant accumulated experience and knowledge as a CRO pioneer. CMIC utilize PVC to create new value in the healthcare field.
For details, visit www.cmic-holdings.co.jp/e/.
goBalto is the industry leader in cloud-based study startup software for the global life sciences industry. Committed to accelerating clinical trials through innovation, product excellence, and customer success, goBalto works with over half of top 20 Pharma and top 10 CROs. Our customers include: Novartis, Genentech Roche, ICON, INC Research and Covance. goBalto is headquartered in San Francisco, with offices in Pennsylvania and Singapore. For more information, visit www.gobalto.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cmic-holdings-a-leading-cro-in-asia-implements-gobalto-activate-to-accelerate-study-startup-300318451.html
SOURCE goBalto, Inc.